Accessibility StatementSkip Navigation MILWAUKEE, Nov. 24, 2025 /PRNewswire/ -- Harley-Davidson Financial Services, Inc. (the "Company" or "HDFS"), a subsidiary of Harley-Davidson, Inc., today announced the expiration and results of its tender offers to purchase for cash (the "Offers") any and all of its outstanding 6.500% Medium-Term Notes due 2028 (the "2028 Notes") and 5.950% Medium-Term Notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes"). The Offers were made under the Offe ...

LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price of up to approximately $194.4 million. The Tender Offer expired at 5:00 p.m. Eastern Time on November 18, 2025. The expiration of the Tender Offer concludes the Company ...

Core Viewpoint - Harley-Davidson Financial Services, Inc. has initiated tender offers to purchase all Medium-Term Notes issued by the company, aiming to manage its debt obligations effectively [1][2]. Summary by Relevant Sections Tender Offers - The tender offers are made for cash purchases of Medium-Term Notes, with specific details outlined in the Offer to Purchase dated November 17, 2025 [1][2]. - The principal amounts of the Medium-Term Notes include $700 million for 6.500% Notes due 2028 and $500 million for 5.950% Notes due 2029 [2]. Consideration and Terms - The consideration for each $1,000 principal amount of Notes will be determined based on a fixed spread plus the yield to maturity of the applicable U.S. Treasury Reference Security [2]. - The Offers will expire at 5:00 p.m. New York City time on November 21, 2025, unless extended or terminated [2][6]. Settlement and Withdrawal - The expected settlement date for validly tendered Notes is November 24, 2025, with a separate settlement for those tendered through Guaranteed Delivery Procedures expected on November 26, 2025 [4][5]. - Holders can withdraw their tendered Notes at any time before the expiration date, but not thereafter unless required by law [6]. Conditions and Management - The acceptance of Notes for purchase is subject to the satisfaction or waiver of certain conditions set forth in the Offer to Purchase [7]. - The company has the discretion to amend the Offers and extend deadlines as necessary [2][6]. Contact Information - J.P. Morgan, TD Securities, and Wells Fargo Securities are the lead dealer managers for the tender offers, providing assistance to investors [9].

Core Viewpoint - Brunswick Corporation has initiated a tender offer to purchase up to $50 million of its 5.100% Senior Notes due 2052, indicating a strategic move to manage its debt obligations and optimize its capital structure [1][2]. Offer Details - The tender offer will expire at 5:00 p.m. Eastern Time on December 11, 2025, unless extended or terminated earlier by the company [2]. - Tenders can be withdrawn until 5:00 p.m. Eastern Time on November 25, 2025, unless extended [2]. - The total consideration for validly tendered notes will be determined based on a fixed spread over the yield of a specified U.S. Treasury Security, including an early tender premium of $50 per $1,000 principal amount [3][6]. Payment and Settlement - Payments for purchased notes will include accrued and unpaid interest, with the expected early settlement date being December 1, 2025, for notes tendered by the early tender deadline [5][7]. - The settlement date for notes tendered after the early tender deadline is expected to be December 15, 2025 [7]. Tender Conditions - Tenders must be in principal amounts of at least $2,000 and in multiples of $1,000 [4]. - The company reserves the right to adjust the tender cap, which may affect the total amount of notes purchased [10]. - The offer is not subject to a minimum tender condition, but may be subject to proration if the total tendered amount exceeds the tender cap [11][9]. Company Overview - Brunswick Corporation is a leader in marine recreation, offering a wide range of products and services across various brands, including Mercury Marine and Sea Ray [18]. - The company operates globally with approximately 15,000 employees and has been recognized for its workplace culture and innovation [19].

Core Viewpoint - LAVA Therapeutics N.V. is urging its shareholders to tender their shares in the ongoing acquisition offer from XOMA Royalty Corporation before the expiration deadline of November 12, 2025, to avoid potential risks associated with the failure of the transaction [1][3][12]. Group 1: Transaction Details - On August 4, 2025, LAVA and XOMA entered into a share purchase agreement, with XOMA extending its offer to purchase all outstanding common shares of LAVA until November 12, 2025 [2]. - The LAVA Board unanimously recommends that shareholders tender their shares to ensure the completion of the offer [3]. Group 2: Risks of Non-Completion - If the requisite percentage of shares is not tendered, the offer cannot be completed, which may lead to significant risks for shareholders, including potential liquidation and dissolution of LAVA [3][6]. - In the event of non-completion, LAVA's share price may decline, particularly if the current market price reflects expectations of the offer being completed [6]. Group 3: Share Tendering Process - Shareholders holding LAVA shares through brokers are advised to instruct their brokers to tender their shares promptly to meet processing deadlines [4][5]. - Those who have previously tendered their shares do not need to take any further action due to the extension of the offer [8]. Group 4: Company Overview - LAVA Therapeutics is a biopharmaceutical company focused on developing bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, with partnerships including Johnson & Johnson and Pfizer [9].

Core Viewpoint - Taylor Morrison Home Corporation announced the expiration of its cash tender offer for its outstanding 5.875% Senior Notes due 2027, which took place from November 3 to November 7, 2025, with valid tenders amounting to approximately $479.155 million, representing 95.83% of the total outstanding amount of $500 million [1][3][4]. Group 1: Tender Offer Details - The cash tender offer was initiated by Taylor Morrison Communities, Inc., a wholly owned subsidiary of Taylor Morrison Home Corporation [1]. - The expiration time for the tender offer was set for 5:00 p.m. New York City time on November 7, 2025 [1]. - The purchase price for the validly tendered notes was set at $1,023.07 per $1,000 principal amount [3]. Group 2: Financial Implications - The Offeror plans to use a portion of the proceeds from a new issuance of $525 million aggregate principal amount of 5.750% senior notes due 2032 to fund the payment for the notes purchased in the tender offer [4]. - Payment for the validly tendered notes is expected to occur on November 10, 2025 [4]. Group 3: Future Actions - Following the settlement of the tender offer, the Offeror intends to redeem any outstanding notes that were not purchased [5]. - A conditional notice of redemption has been issued for any remaining notes, with a target redemption date around December 2, 2025, contingent upon receiving sufficient funds from the senior notes offering [5]. Group 4: Company Background - Taylor Morrison is recognized as one of the leading homebuilders and developers in the United States, serving a diverse range of consumers across various market segments [8].

Group 1 - Landsbankinn hf. announced a tender offer for its EUR 2027 notes, allowing holders to sell their notes back to the bank for cash [1] - The tender offer is subject to specific terms and conditions outlined in the tender offer memorandum dated 27 October 2025, which includes the outcome of the bank's intended new issuance [1] - Further details regarding the tender offer can be found in the announcement published on Euronext Dublin, where the bonds are listed [2] Group 2 - The tender offer memorandum can be obtained from the tender agent, Kroll Issuer Services Limited, subject to certain distribution restrictions [2] - The joint lead managers for this tender offer include ABN AMRO Bank, BofA Securities Europe, Natixis, and NatWest Markets [2] - This announcement may contain inside information as defined by the Market Abuse Regulation (EU) 596/2014 [3]

Core Points - Novartis announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in relation to its tender offer to acquire Tourmaline Bio at a price of $48.00 per share in cash [1][2] - The expiration of the HSR Act waiting period is a necessary condition for the completion of the merger agreement dated September 8, 2025, which includes the tender offer and subsequent merger [2] - The tender offer will expire at 11:59 p.m. Eastern Time on October 27, 2025, unless extended or terminated earlier [2] Company Information - Novartis is an innovative medicines company focused on improving and extending people's lives through its products, reaching over 300 million people globally [7]

Core Points - Keros Therapeutics, Inc. has initiated a cash tender offer to repurchase up to $194.4 million of its common stock at a price of $17.75 per share as part of a $375 million capital return program [1] - The tender offer is set to expire on November 18, 2025, unless extended or terminated earlier [2] - Keros plans to fund the tender offer using its existing cash and cash equivalents [1] Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional signaling of the TGF-ß protein family [6] - The company is recognized for its understanding of TGF-ß proteins, which regulate the growth and maintenance of various tissues [6] - Keros' lead product candidate, KER-065, targets neuromuscular diseases, particularly Duchenne muscular dystrophy, while its advanced candidate, elritercept, is aimed at treating cytopenias in myelodysplastic syndrome and myelofibrosis patients [6]

Core Points - Kvika Banki hf. announced the results of its tender offer for SEK 566 million and NOK 750 million Senior Unsecured FRNs [1][2] - The tender offer expired on 9 October 2025, with a total nominal amount of SEK 756 million validly tendered [2][3] - All validly tendered notes will be repurchased, leaving outstanding amounts of SEK 227 million and NOK 333 million [3] Summary by Sections - **Tender Offer Details** - The tender offer was for a combined total nominal amount of 750 million at a purchase price of 102.150%, plus accrued and unpaid interest [1] - The settlement of the tender offer is expected to occur on 16 October 2025 [3] - **Dealer Manager Information** - Nordea Bank Abp was mandated as the dealer manager for the tender offer [4] - **Regulatory Disclosure** - The announcement is a disclosure of inside information per EU regulation on market abuse [5]